Clinical significance of coagulation assays in metastatic pancreatic adenocarcinoma

Journal of Gastrointestinal Cancer

Volumn 44, Issue 4, 2013, Pages 404-409

  Tas, Faruk ^a   Karabulut, Senem ^a   Bilgin, Elif ^a   Kılıc, Leyla ^a   Ciftci, Rumeysa ^a   Duranyildiz, Derya ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Coagulation; Metastatic; Pancreatic adenocarcinoma; Test

Indexed keywords

BLOOD CLOTTING FACTOR; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CISPLATIN; D DIMER; FIBRINOGEN; GEMCITABINE;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD CLOTTING DISORDER; BLOOD CLOTTING TEST; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CLINICAL ARTICLE; CONTROL GROUP; CONTROLLED STUDY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FIBRINOLYSIS; HUMAN; INTERNATIONAL NORMALIZED RATIO; MALE; MEDICAL HISTORY; PANCREAS ADENOCARCINOMA; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTHROMBIN TIME; THROMBOCYTE COUNT; UNIVARIATE ANALYSIS;

ADENOCARCINOMA; ADULT; AGED; BLOOD COAGULATION TESTS; CASE-CONTROL STUDIES; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBRINOGEN; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PANCREATIC NEOPLASMS; PROGNOSIS; PROTHROMBIN TIME; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84888200594     PISSN: 19416628     EISSN: 19416636     Source Type: Journal    
DOI: 10.1007/s12029-013-9512-8     Document Type: Article

References (30)

1. Lyman GH, Khorana AA. Cancer, clots and consensus: new understanding of an old problem. J Clin Oncol. 2009;27:4821-6.
2. Dvorak HF. Thrombosis and cancer. Hum Pathol. 1987;18:275-84.
3. Buccheri G, Ferrigno D, Ginardi C, Zuliani C. Haemostatic abnormalities in lung cancer: prognostic implications. Eur J Cancer. 1997;33:50-5.
4. Palumbo JS, Kombrinck KW, Drew AF, Grimes TS, Kiser JH, Degen JL, et al. Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells. Blood. 2000;96:3302-9.
5. Malik G, Knowles LM, Dhir R, Xu S, Yang S, Ruoslahti E, et al. Plasma fibronectin promotes lung metastasis by contributions to fibrin clots and tumor cell invasion. Cancer Res. 2010;70:4327-34.
6. Brown LF, Guidi AJ, Schnitt SJ, Van De Water L, Ireula-Arispe M-L, Yeo T-K, et al. Vascular stroma formation in carcinoma in situ, invasive carcinoma, and metastatic carcinoma of the breast. Clin Cancer Res. 1999;5:1041-56.
7. Oya M, Akiyama Y, Okuyama T, Ishikawa H. High preoperative plasma D-dimer level is associated with advanced tumor stage and short survival after curative resection in patients with colorectal cancer. Jpn J Clin Oncol. 2001;31:388-94.
8. Nagy Z, Horváth O, Kádas J, Valtinyi D, László L, Kopper B, et al. D-dimer as a potential prognostic marker. Pathol Oncol Res. 2012;18:669-74.
9. Ay C, Dunkler D, Pirker R, Thaler J, Quehenberger P, Wagner O, et al. High D-dimer levels are associated with poor prognosis in cancer patients. Haematologica. 2012;97:1158-64.
10. Ay C, Vormittag R, Dunkler D, Simanek R, Chiriac AL, Drach J, et al. D-dimer and prothrombin fragment 1 + 2 predict venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study. J Clin Oncol. 2009;27:4124-9.
11. Wang HY, Xiu DR, Li ZF, Wang G. Coagulation functions in patients with pancreatic carcinoma. Chin Med J (Engl). 2009;122:697-700.
12. Ni XG, Bai XF, Mao YL, Shao YF, Wu JX, Shan Y, et al. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer. Eur J Surg Oncol. 2005;31:164-9.
13. Zacharski LR, Wojtukiewicz MZ. Pathways of coagulation/fibrinolysis activation in malignancy. Semin Thromb Haemost. 1992;18:104-6.
14. Gabazza EC, Taguchi O, Yamakami T, Machishi M, Ibata H, Suzuki S. Evaluating prethrombotic state in lung cancer using molecular markers. Chest. 1993;103:196-200.
15. Edwards RL, Rickles FR, Moritz TE, et al. Abnormalities of blood coagulation tests in patients with cancer. Am J Pathol. 1987;88:596-602.
16. Bartoloni C, Guidi L, Tricerri A, et al. Latent coagulation disorders evaluated by the assay of plasma thrombin antithrombin III complexes in a large series of 'solid tumors'. Oncology. 1992;49:426-30.
17. Yamaguchi T, Yamamoto Y, Yokota S, Nakagawa M, Ito M, Ogura T. Involvement of interleukin-6 in the elevation of plasma fibrinogen levels in lung cancer patients. Jpn J Clin Oncol. 1998;28:740-4.
18. Rose PG, Terrien JM, Baker S. Plasma D dimer and peritoneal CA-125 levels as predictors of disease status in ovarian carcinoma. J Surg Oncol. 1994;56:168-71.
19. Blackwell K, Hurwitz H, Liebérman G, Novotny W, Snyder S, Dewhirst M, et al. Circulating D-dimer levels are better predictors of overall survival and disease progression than carcinoembryonic antigen levels in patients with metastatic colorectal carcinoma. Cancer. 2004;101:77-82.
20. Falanga A. Thrombophilia in cancer. Semin Thromb Hemost. 2005;31:104-10.
21. Owen CAJ, Bowie EJW, Thompson JHJ. The diagnosis of bleeding disorders. Boston: Little, Brown & Company; 1975.
22. Madoiwa S, Komatsu N, Mimuro J, et al. Developmental expression of plasminogen activator inhibitor- I (PAI-I) associated with thrombopoietin- dependent megakaryocytic differentiation. Blood. 1999;94:475-82.
23. Lindahl AK, Odegaard OR, Sandset PM, Harbitz TB. Coagulation inhibition and activation in pancreatic cancer. Changes during progress of disease. Cancer. 1992;70:2067-72.
24. Khorana AA, Ahrendt SA, Ryan CK, Francis CW, Hruban RH, Hu YC, et al. Tissue factor expression, angiogenesis, and thrombosis in pancreatic cancer. Clin Cancer Res. 2007;13:2870-5.
25. Delluc A, Rousseau A, Delluc C, Le Moigne E, Le Gal G, Mottier D, et al. Venous thromboembolism in patients with pancreatic cancer: implications of circulating tissue factor. Blood Coagul Fibrinolysis. 2011;22:295-300.
26. Saito Y, Hashimoto Y, Kuroda J, Yasunaga M, Koga Y, Takahashi A, et al. The inhibition of pancreatic cancer invasion-metastasis cascade in both cellular signal and blood coagulation cascade of tissue factor by its neutralisation antibody. Eur J Cancer. 2011;47:2230-9.
27. Van den Berg YW, Osanto S, Reitsma PH, Versteeg HH. The relationship between tissue factor and cancer progression: insights from bench and bedside. Blood. 2012;119:924-32.
28. Akl EA, Rohilla S, Barba M, Sperati F, Terrenato I, Muti P, et al. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer: a systematic review. Cancer. 2008;113:1685-94.
29. Mandalà M, Tondini C. The impact of thromboprophylaxis on cancer survival: focus on pancreatic cancer. Expert Rev Anticancer Ther. 2011;11:579-88.
30. Nakchbandi IA, Löhr JM. Coagulation, anticoagulation and pancreatic carcinoma. Nat Clin Pract Gastroenterol Hepatol. 2008;5:445-55.